TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Guangzhou Baiyunshan Pharmaceutical Holdings Company ( (HK:0874) ).
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited announced that its subsidiary, Guanghua, has entered into a Land Reserve Compensation Agreement with the Tonghe Sub-district Office for a land parcel located in Baiyun District, Guangzhou. The agreement entails a compensation amount of RMB375,244,134, with an additional land handover incentive of approximately RMB73,323,768, contingent upon meeting certain conditions. This agreement is part of the ‘Implementation Plan for Land Reserve in Baiyun Tonghe Area’ and could potentially impact the company’s operations by providing significant financial compensation, which may be used for future investments or operational enhancements.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
More about Guangzhou Baiyunshan Pharmaceutical Holdings Company
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is a joint stock company with limited liability established in the People’s Republic of China. The company operates in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical products and services.
Average Trading Volume: 1,259,773
Technical Sentiment Signal: Buy
Current Market Cap: HK$44.18B
See more data about 0874 stock on TipRanks’ Stock Analysis page.